Patents by Inventor Andrew Christopher Flick

Andrew Christopher Flick has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • RORC2 INHIBITORS AND METHODS OF USE THEREOF
    Publication number: 20170233371
    Abstract: The present invention provides compounds, pharmaceutical compositions, methods of inhibiting ROR? activity and/or reducing the amount of IL-17 in a subject, and methods of treating various medical disorders using such compounds and pharmaceutical compositions.
    Type: Application
    Filed: April 26, 2017
    Publication date: August 17, 2017
    Applicant: Pfizer Inc.
    Inventors: Mark Edward Schnute, Gõran Mattias Wennerstål, James Robert Blinn, Neelu Kaila, James Richard Kiefer, Jr., Scot Richard Mente, Ravi G. Kurumbail, Marvin Jay Meyers, Atli Thorarensen, Li Xing, Christoph Wolfgang Zapf, Edouard Zamaratski, Andrew Christopher Flick, Peter Jones
  • Methyl- and Trifluoromethyl-Substituted Pyrrolopyridine Modulators of RORC2 and Methods of Use Thereof
    Publication number: 20170233390
    Abstract: The present invention provides methyl- and trifluoromethyl-substituted pyrrolopyridines, pharmaceutical compositions thereof, methods of modulating ROR? activity and/or reducing the amount of IL-17 in a subject, and methods of treating various medical disorders using such pyrrolopyridines and pharmaceutical compositions thereof.
    Type: Application
    Filed: April 28, 2017
    Publication date: August 17, 2017
    Applicant: Pfizer Inc.
    Inventors: MARK EDWARD SCHNUTE, ANDREW CHRISTOPHER FLICK, PETER JONES, NEELU KAILA, SCOT RICHARD MENTE, JOHN DAVID TRZUPEK, MICHAEL L. VAZQUEZ, GÖRAN MATTIAS WENNERSTÅL, LI XING, EDOUARD ZAMARATSKI, LIYING ZHANG
  • Methyl- and trifluoromethyl-substituted pyrrolopyridine modulators of RORC2 and methods of use thereof
    Patent number: 9670201
    Abstract: The present invention provides methyl- and trifluoromethyl-substituted pyrrolopyridines, pharmaceutical compositions thereof, methods of modulating ROR? activity and/or reducing the amount of IL-17 in a subject, and methods of treating various medical disorders using such pyrrolopyridines and pharmaceutical compositions thereof.
    Type: Grant
    Filed: September 24, 2015
    Date of Patent: June 6, 2017
    Assignee: Pfizer Inc.
    Inventors: Mark Edward Schnute, Andrew Christopher Flick, Peter Jones, Neelu Kaila, Scot Richard Mente, John David Trzupek, Michael L. Vazquez, Göran Mattias Wennerstål, Li Xing, Edouard Zamaratski, Liying Zhang
  • Methyl- and Trifluoromethyl-Substituted Pyrrolopyridine Modulators of RORC2 and Methods of Use Thereof
    Publication number: 20160090381
    Abstract: The present invention provides methyl- and trifluoromethyl-substituted pyrrolopyridines, pharmaceutical compositions thereof, methods of modulating ROR? activity and/or reducing the amount of IL-17 in a subject, and methods of treating various medical disorders using such pyrrolopyridines and pharmaceutical compositions thereof.
    Type: Application
    Filed: September 24, 2015
    Publication date: March 31, 2016
    Inventors: MARK EDWARD SCHNUTE, ANDREW CHRISTOPHER FLICK, PETER JONES, NEELU KAILA, SCOT RICHARD MENTE, JOHN DAVID TRZUPEK, MICHAEL L. VAZQUEZ, GÖRAN MATTIAS WENNERSTÅL, LI XING, EDOUARD ZAMARATSKI, LIYING ZHANG
  • RORC2 INHIBITORS AND METHODS OF USE THEREOF
    Publication number: 20160046597
    Abstract: The present invention provides compounds, pharmaceutical compositions, methods of inhibiting ROR? activity and/or reducing the amount of IL-17 in a subject, and methods of treating various medical disorders using such compounds and pharmaceutical compositions.
    Type: Application
    Filed: July 31, 2014
    Publication date: February 18, 2016
    Inventors: Mark Edward Schnute, Göran Mattias Wennerstål, James Robert Blinn, Neelu Kaila, James Richard Kiefer, JR., Scot Richard Mente, Ravi G. Kurumbail, Marvin Jay Meyers, Atli Thorarensen, Li Xing, Christoph Wolfgang Zapf, Edouard Zamaratski, Andrew Christopher Flick, Peter Jones